Clin2
NCT05922878Possibly a fitRecruiting

ALTO-300 study for moderate to severe depression

Major Depressive Disorder

Part of Mental health clinical trials.

This trial tests ALTO-300 as an add-on treatment for people with moderate to severe major depressive disorder (MDD). It aims to see whether ALTO-300 helps improve depression symptoms when you’re already on a stable antidepressant.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
321 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You have been diagnosed with moderate to severe major depression
  • You are currently on one antidepressant (an SSRI, an SNRI, or bupropion) and have stayed on the same dose for at least 6 weeks
  • You can follow all study visits, questionnaires, and other required study activities
  • You cannot be pregnant or breastfeeding during the study
  • You do not have serious unstable medical problems or conditions that make participation unsafe

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06633016Recruiting· Phase 2
ABX-002 for major depression (add-on treatment)

This trial tests a new medication called ABX-002 as an add-on to your current antidepressant. It's for people with moderate to severe depression who haven't gotten enough help from their current antidepressant alone.

Birmingham, Alabama
NCT06236880Recruiting· Phase 2
Testing GM-2505 for Moderate to Severe Depression

This trial tests a new oral medication, GM-2505, for people with moderate to severe major depressive disorder (MDD). The goal is to see if it is safe and well-tolerated, either as a stand-alone treatment or alongside a stable SSRI/SNRI antidepressant.

Manchester
NCT07196501Recruiting· Phase 3
Study of a new add-on treatment for depression maintenance

This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.

Oceanside, California
NCT05850689Recruiting· Phase 3
Lumateperone add-on for major depression that didn’t improve

This study tests whether adding lumateperone to an antidepressant helps adults with major depressive disorder (MDD) who haven’t improved enough after trying at least two different antidepressants. It may help reduce depressive symptoms more than antidepressants alone.

Huntsville, Alabama
NCT06966401Recruiting· Phase 3
Long-term safety study of a new depression treatment

This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.

Huntsville, Alabama
NCT06656416Recruiting· Phase 2
ALTO-100 for bipolar depression

This trial tests an investigational drug called ALTO-100 in people with bipolar I or II who are currently experiencing depression. It looks at whether this new medicine can help improve depression symptoms when taken alongside your usual mood stabilizer or antipsychotic medication.

Chandler, Arizona

Hear when a new Major Depressive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.